NATURA-BISSÉ
22.11.2023 10:01:38 CET | Business Wire | Press release
Natura Bissé & Arch Amenities Group Europe have announced a formal collaboration to increase their collective presence in the luxury spa sector across the EU and the United Kingdom. The agreement fosters strategic and complementary growth opportunities for both brands, which will reference each other, capitalizing on the well-established reputation of the Natura Bissé brand, its professional and retail skincare products and services and Arch Amenities Group’s experience in managing and operating pre-eminent luxury wellness centers and spas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231122952800/en/
Barry Goldstein, CEO Arch Amenities Group (Photo: Natura Bissé)
The Spanish skincare firm, Natura Bissé, currently has a presence in more than 450 spa hotels around the world—35% of which are located in Europe—and is set to close the year with a total revenue of 100 million euros. With its headquarters in Barcelona, 82% of the company’s sales are recorded abroad, with the Unites States and China being its primary markets, followed by Spain. Over the next 3 years, Europe will become the company’s strategic focus with the aim of doubling its multi-channel presence in this region.
For its part, Arch Amenities Group and its 3800 employees currently manage over 430 properties around the world. Private clubs, fitness centers, commercial and residential spaces and, of course, hotels place their trust in the Group’s extensive experience. Among the hotel groups in their portfolio of clients are big names like Waldorf Astoria, Four Seasons and The Ritz-Carlton, who are also partners of Natura Bissé across the world.
Natura Bissé has been part of Arch Amenities Group’s Preferred Vendor Program since early 2023, connecting the Natura Bissé product suite to a host of renowned U.S.-based spas and wellness spaces such as the Eden Roc Miami Beach Resort or the Waldorf Astoria Washington DC.
Today this partnership adopts a new character as a “non-exclusive strategic agreement” in Europe, at a time when the hospitality sector is seeing increased demand for elevated wellness experiences. Proof of this comes from data in a recent report from the Global Wellness Institute, which highlights consistent 12% annual growth in the wellbeing market since 2020 and forecasts a further 52% growth by 2027.
“This strategic agreement represents a step-change in the way both leading brands address the changing needs of the European market and reinforces our collective commitment to offer unlimited innovation, inspiration as a pillar of growth and bespoke agile solutions. That is why I’m convinced that our collaboration with Arch Amenities Group Europe will allow us to expand our presence in first-class spas and wellbeing centers,” says Verónica Fisas, CEO at Natura Bissé Group.
“Partnering with Natura Bissé in Europe to develop spas is an ideal fit for Arch as we grow our presence in Europe. As one of the most celebrated luxury skincare brands in the world, our strategic collaboration with Natura Bissé allows us to extend our proven expertise in developing and managing luxury wellness spaces to bring guests an unparalleled experience powered by great products, outstanding hospitality and elevated service,” says Barry Goldstein, CEO at Arch Amenities Group.
ABOUT ARCH AMENITIES GROUP
Arch Amenities Group, based in Rockville, Maryland, is a leading provider of hospitality management and consulting services for commercial and residential properties, hotels, spas and private clubs and recreation spaces worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy as well as recruiting, pre-opening and sustaining strategy and support. Arch is a portfolio company of private equity firm CI Capital Partners.
ABOUT NATURA BISSÉ
Natura Bissé is a globally renowned luxury skincare company. Founded in Barcelona in 1979, Natura Bissé fuses pioneering technology with the most delicate human touch in order to listen and adapt to the differing needs of each and every client.
The constant pursuit of excellence has earned Natura Bissé numerous awards, notably recognition for being the “World’s Best Spa Brand” for four consecutive years (2018-2021).
With presence in 40 countries, Natura Bissé continues to expand around the world throughout the most distinguished luxury retailers and best-in-class spas.
In 2008 the brand helped establish the Ricardo Fisas Natura Bissé Foundation to contribute to the well-being of people in vulnerable situations. To support the Foundation’s initiatives, Natura Bissé has three fundraising lines of hotel toiletries.
Images available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122952800/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
